U.S., Jan. 27 -- ClinicalTrials.gov registry received information related to the study (NCT07367724) titled 'Ademetionine in Obstructive Hypertrophic Cardiomyopathy' on Dec. 25, 2025.
Brief Summary: This study is a multicenter, double-blind, randomized controlled Phase 2 trial designed to evaluate the safety and efficacy of Ademetionine in patients with obstructive hypertrophic cardiomyopathy (oHCM). The study will recruit patients with oHCM who, under double-blind conditions, will be randomly assigned to either the Ademetionine group or the placebo group. Follow-up visits will be conducted every 4 weeks until 16 weeks from baseline. After 16 weeks, the study will evaluating the effect of Ademetionine on exercise capacity, heart failure sy...